CDDF
Cancer Drug Development Forum

THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. INNOVATE. DEBATE. COMMUNICATE.

Facilitating Debate, Fostering Innovation,
Accelerating Access to the Best Treatments
for All Cancer Patients

info@cddf.org
www.cddf.org

CDDF
Cancer Drug Development Forum

WHAT IS THE CDDF

The Cancer Drug Development Forum (CDDF) is a **non-profit organisation** registered in **Belgium** that provides a **neutral platform** to stimulate **interaction between stakeholders** involved in **cancer drug development.**

OUR MISSION

The CDDF's mission is to **provide a trusted space for all stakeholders** in cancer drug development to **facilitate dialogue, debate, and communication**, **fostering innovation** to **accelerate access to new (or the best) treatments** for all patients.

HOW WE ADVANCE OUR MISSION

- The CDDF provides **a non-competitive, non-commercial platform** for **multi-stakeholder discussions** and **collaboration.**
- The CDDF **brings together all actors** in the oncology community such as **academia,** the **healthcare industry, regulatory authorities**, **health technology assessment (HTA) bodies**, **policymakers,** and **patient advocacy groups.**
- The CDDF **stimulates advancement and innovation** in the field through **scientific debate** and **open discussion.**

INITIATIVES

Since 2001, the Cancer Drug Development Forum (CDDF) has served as a **trusted space for all stakeholders** in cancer drug development to **facilitate dialogue, debate and communication**, fostering innovation to **accelerate access to new treatments for patients.**

The CDDF champions progress by hosting **dynamic conferences, workshops, conferences, webinars, and projects** that bring together stakeholders involved in oncology. In a **neutral, non-competitive environment**, we foster **productive dialogue and open, respectful interactions** in collaboration with the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and regulators from Europe and worldwide, alongside with academic researchers, pharmaceutical companies, HTA bodies, and patient advocates. Together, we **accelerate breakthroughs** and **access to effective treatments for all patients**.



FACILITATE. DEBATE. ACTIVATE. INNOVATE.

As a key part of the effort, the CDDF holds its **Annual Conference** that gathers key stakeholders and experts to address **challenges and opportunities in oncology drug development**. This interactive three-day meeting features plenary lectures with moderated discussions, offering multistakeholder perspectives and unique networking opportunities.

In addition to the Conference, the CDDF organizes **workshops, webinars and EU-level projects** to facilitate multi-stakeholder collaboration on **topical issues in the field of oncology**. The **responsive nature** of the CDDF platform enables the oncology community to initiate **timely conversations to reflect current and pressing needs**. We continue pioneering progress through upcoming programs, which explore the impact of digital AI approaches in discovery research and global and EU regulatory landscapes.

Through the **publication of white papers**, the CDDF goes the extra mile by **translating its meeting outcomes into actionable insights**, driving incremental, significant shifts in oncology.

We believe that **continued dialogue and active collaboration** are key to improving cancer treatments and accelerating patient access. We welcome all our stakeholders to join us in advancing this mission and making their voices heard.

CDDF
Cancer Drug Development Forum

CDDF MEETINGS BRING TOGETHER REGULATORS, HTAs, THE HEALTHCARE INDUSTRY, ACADEMICS, AND PATIENT ADVOCATES TO COLLABORATE

INCLUSIVE & COLLABORATIVE NETWORK OF MULTI-STAKEHOLDERS INVOLVED IN ONCOLOGY DRUG DEVELOPMENT

CDDF LEADERSHIP

The CDDF is governed by a rotating board of directors, elected for three-year terms, dedicated to accelerating and optimizing cancer drug development and patient access. The board comprises distinguished individuals, including a patient advocate, pre-clinical and clinical investigators, medical oncologists, a pediatrician, and regulatory scientists, representing diverse perspectives within the drug development process.

These committed members bring vast experience from clinical, patient advocacy, industry and regulatory settings, ensuring the CDDF effectively functions as a neutral, non-competitive platform for all stakeholders involved in cancer drug development.

CDDF BOARD OF DIRECTORS

Mark Lawler
Chairperson

Ruth Plummer
Managing Director

Stefan Symeonides
Vice-Chairperson

Axel Glasmacher
Treasurer

Jaap Verweij

Rosa Giuliani

Christian Schneider

Fergus Sweeney

Agnès Saint-Raymond

Jana Pelouchova

CDDF OFFICE

CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.

Thierry Coppens
Director of Operations

Giorgia Campagnano
Event Manager

Shannon Adeux
Event Coordinator

Hyunmin Park
Community & Communication Coordinator

CDDF ACTIVITIES 2026

MULTI-STAKEHOLDER DISCUSSIONS

- **Executive summary**
- **Recordings/slides***

- **Executive summary**
- **Recordings/slides**
- **White paper (available soon)**

- **Workshop programme**
- **Registration**

**Recent meeting recordings, slides and publications are accessible exclusively to the CDDF Industry Members via the CDDF Intranet platform. Sign up for the member access here: https://cddf.org/member-access/*

CDDF LIVE WEBINARS

- Key takeaways
- Recording/slides

- Key takeaways
- Recording/slides

- Webinar outline
- Registration

Webinars in the Planning Stage

- CDDF Diversity Initiative paper
- Learning from “facilitating and accelerating strategic clinical trials in the EU” **pilot FAST EU**

MULTI-STAKEHOLDER DISCUSSIONS

- **Executive summary**
- **Recordings/slides**
- **White paper: Challenges and Potential Solutions to Advance Global Cancer Drug Development** (Therapeutic Innovation & Regulatory Science, March 2026)



- **Executive summary**
- **Recordings/slides***
- **White paper (available soon)**

- **Executive summary**
- **Recordings/slides***
- **White paper (available soon)**

CDDF
Cancer Drug Development Forum
FACILITATE. INNOVATE. DEBATE. COMMUNICATE.

**Recent meeting recordings, slides and publications are accessible exclusively to the CDDF Industry Members via the CDDF Intranet platform. Sign up for the member access here: https://cddf.org/member-access/*

MEETING OUTCOMES 2025

LIVE WEBINARS

- Key takeaways
- Recordings/slides



- Key takeaways
- Recordings/slides

- Key takeaways
- Recordings/slides

- Key takeaways
- Recordings/slides

- Key takeaways
- Recordings/slides

- Key takeaways
- Recordings/slides

CDDF INDUSTRY MEMBERS PLATFORM

WHAT IS THE CDDF INDUSTRY MEMBERS' PLATFORM?

The CDDF Industry Members' Platform is composed of large and SME members from the healthcare industry who support the CDDF in its mission to establish a neutral space for stakeholders to facilitate discussion on innovative drug development in oncology.

The Industry Members' Platform acts as an advisory body within the CDDF. It supports the association in compliance with all relevant regulations in a manner consistent with the non-competitive, non-commercial platform that the CDDF offers to all stakeholders.

WHY JOIN THE CDDF INDUSTRY MEMBERS' PLATFORM?

- Stimulate advancement in oncology treatment and delivery
- Identify and overcome challenges in the development of cancer drugs
- Improve product time to market for new treatments

CONTRIBUTE TO THE **DEVELOPMENT** OF
CANCER DRUGS AND **TREATMENTS**

BECOME A MEMBER OF THE CDDF

INDUSTRY MEMBER BENEFITS

1 Unique Platform for Multi-Stakeholder Discussions

Access to the CDDF Industry Members' Platform to join members in addressing challenges in cancer drug development from a multi-stakeholder perspective

2 Complimentary Registration

Complimentary registration for in-person participants at every CDDF hybrid event *(one for small businesses, two for medium-sized enterprises and four for large healthcare companies)*.

3 Livestream Access

Livestream access to all CDDF conferences, workshops and webinars.

4 Early Access to Digital Content

Early access to digital content from the CDDF's conference, workshops and webinars before public release.

BECOME A MEMBER OF THE CDDF

INDUSTRY MEMBER BENEFITS

5 Professional Contribution

Professional contribution to CDDF's scientific programme and the chance to collaborate with various stakeholders on developing content for CDDF meetings.

6 Access to a Reputable Oncology Network

Access to a reputable oncology network and opportunities to connect informally with representatives from academia, regulatory authorities, HTAs, and patient groups.

CDDF INDUSTRY MEMBERSHIP PACKAGES

	Start-up or small business	Medium-sized enterprise	Large healthcare company
Criteria	No oncology product on the market and Revenues ≤ € 50 million	**Either** low revenues and at least one oncology product on the market **or** medium or large revenues and no oncology product on the market	At least one oncology product on the market and Revenues ≥ € 1 billion
Membership fee 2027 *	**€ 8,400**	**€ 21,625**	**€ 48,175**

**The membership fee is subject to an annual adjustment in line with the Belgian consumer price index for the previous year. Members are notified of fee inflation in September.*

BENEFITS

Access the CDDF Industry Members Platform	✓	✓	✓
Free registration for every CDDF event	1	2	4
Livestream access to CDDF workshops and conference	5	15	Unlimited
Early access to digital content from the CDDF discussions before public release	5	15	Unlimited
Contribution to CDDF's scientific programme and collaboration with multi-stakeholders	✓	✓	✓

COLLABORATION AND **OPEN DIALOGUE** AMONG ALL STAKEHOLDERS ARE **KEY** TO IMPROVING OUTCOMES FOR CANCER PATIENTS

info@cddf.org

www.cddf.org

@cddf_eu

The Cancer Drug Development Forum (CDDF)

Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

The CDDF is a non-profit association in the register of legal entities at the French Speaking Enterprise Court in Brussels. Enterprise number: 738.523.752